Sichuan Kelun Pharmaceutical

Expanding ADC Pipeline Will Unlock Global Oncology Markets

AnalystConsensusTarget

Not Invested

Consensus Narrative from 7 Analysts

Published

24 Aug 25

Updated

24 Aug 25

AnalystConsensusTarget's Fair Value

CN¥41.21

7.3% undervalued

24 Aug

CN¥38.20

17.4%

1.4%

17.4%

1.4%

Author's Valuation

CN¥41.2

7.3% undervalued

AnalystConsensusTarget Fair Value

Narrative

Updates0

AnalystConsensusTarget Fair Value

CN¥41.2

7.3% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

8.52%

Pharma revenue growth rate

0.58%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

6.83%

Calculation

CN¥3.72b

Earnings '28

21.19x

PE Ratio '28

CN¥78.78b

Market Cap '28

CN¥78.78b

Market Cap '28

1.56b

No. shares '28

CN¥50.60

Share Price '28

CN¥50.60 Share Price '28

Discounted to 2025 @ 6.83% p.a.

CN¥41.50

Fair Value '25